Aug. 11 at 12:51 PM
Piper Sandler reitd
$PRAX OW/
$270.
Following positive Ph2 RADIANT FOS data, we hosted
$PRAX for a fireside chat and learned new details reaffirming vormatrigine's competitive and potentially transformational product profile.
Specifically, mgmt highlighted vormatrigine showed a consistent PK profile in refractory FOS (vs HVs) with a linear response across AUC and Cmax effectively derisking 40 mg may drive deeper efficacy.
Additionally, mgmt specified most discontinuations occurred during weeks 1-3 of RADIANT where blinded Ph2/3 POWER1 data is showing substantially fewer discontinuations thus far. In that vein, mgmt detailed POWER1 is "at-least" 80% powered to show a placebo-adjusted 30% reduction in median seizure frequency where competitor data suggests consistent response across open-label and randomized placebo-controlled trials.
Hence, we came away from the fireside chat even more confident in vormatrigine's value proposition with full RADIANT data and POWER1 completion 4Q25.
$XENE $BHVN